Veeva: Clinical Trial Platform Monopoly With Huge Untapped Opportunities (NYSE:VEEV)

JHVEPhoto Since I presented my ‘Strong Buy’ thesis for Veeva Systems (NYSE:VEEV) in June 2023, their stock price has surged by 21%. I discussed their data analytics and AI capabilities in the healthcare industry. They guide 15.5% revenue growth and 27% adjusted operating income growth for FY25. Veeva clinical platform connects clinical operations and data…

Read More

Veeva Systems: Still Attractively Priced Given Growth Expectations (NYSE:VEEV)

sanjeri/E+ via Getty Images Investment Thesis Veeva Systems Inc. (NYSE:VEEV) helps streamline processes, improve collaboration, and ensure compliance with industry regulations. The business is highly entrenched and returning to attractive growth once again. Furthermore, I make the case that paying 32x forward non-GAAP operating profits for Veeva is attractively priced. Simply put, with more than…

Read More